AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS

drug protocol number
MN39159
drug sponsor
Roche
drug study
Ocrelizumab
drug trial site
KFSH&RC-R
drug status
Terminated
drug phase